Publication

Article

Oncology & Biotech News

December 2010
Volume4
Issue 12

FDA Green-Lights Phase III Trial for Drug-Eluting Microspheres in Liver Cancer

Author(s):

The FDA has given Merit Medical Systems the green light for a phase III clinical trial investigating QuadraSphere Microspheres in patients with primary liver cancer.

The FDA has given Merit Medical Systems the green light for a phase III clinical trial investigating QuadraSphere Microspheres in patients with primary liver cancer. The drug-eluting microspheres release doxorubicin to the tumor and are approved for peripheral arteriovenous malformations and to embolize hypervascular tumors. The phase III study will take place in the United States and abroad, enrolling only those patients whose liver disease is localized and unresectable.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.